Targets of biologic disease‐modifying antirheumatic drugs and risk of multiple myeloma is a research paper published in International Journal of Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 10 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Cancer Institute
Grant: R01CA223662
National Center for Advancing Translational Sciences
Grant: KL2TR002002
National Heart, Lung, and Blood Institute
Grant: R21HL140531
National Institutes of Health
Grant: 5R21HL140531-02
Risk of venous thromboembolism following diagnosis and treatment of multiple myeloma: differences by race
National Institutes of Health
Grant: 3KL2TR002002-02S1
Institutional Career Development
National Institutes of Health
Grant: 5R01CA223662-03
Epigenomic markers of circulating cell-free DNA and treatment outcome in multiple myeloma
FWCI
1.10
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals